EU to purchase further 300 million doses of BioNTech-Pfizer vaccine

The European Commission has proposed to purchase an additional 300 million doses of the COVID-19 vaccine produced by BioNTech and Pfizer

The European Commission has proposed to the EU Member States to purchase an additional 200 million doses of the BioNTech and Pfizer COVID-19 vaccine with the option to acquire another 100 million in the second quarter of 2021.

This would allow the EU to obtain up to 600 million doses of this vaccine. In addition to the BioNTech-Pfizer vaccine, the Moderna vaccine was authorised on 6th January 2021.

The EU has secured up to 2.3 billion doses from the most promising vaccine candidates.

This vaccine portfolio would enable the EU not only to cover the needs of its whole population but also to supply vaccines to neighbouring countries.